摘要
目的 深入探讨儿童ABO血型不相容活体肝移植的临床疗效及预后情况,为该领域的临床实践提供参考.方法 回顾性分析2021-2023年期间在新疆医科大学第一附属医院小儿普外科接受活体肝移植手术的22例患儿的资料.其中,ABO血型相同(ABO-identical,ABO-Id)或相容(ABO-compatible,ABO-C)组共16例,ABO血型不相容(ABO-incompatible,ABO-In)组6例.我们比较了这两组患儿的一般资料、肝移植术后指标、并发症发生情况以及生存情况.结果 两组在移植月龄、性别、手术史、PELD评分、捐献者年龄、无肝期时长、手术时长、术后住院时长、他克莫司全血谷浓度和血肌酐值等方面进行比较,结果显示差异均无统计学意义(P＞0.05).两组受体的整体累积生存率比较差异无统计学意义(P＞0.05).在术后肺部感染、巨细胞病毒感染、排斥反应以及血管并发症的发生率方面,两组间的差异同样无统计学意义(P＞0.05).结论 儿童ABO血型不相容活体肝移植被认为是一种安全有效的治疗方法,不仅可以扩大供肝来源,而且能够有效挽救患儿的生命.
Abstract
Objective The objective of this study is to examine the clinical efficacy and prognosis of ABO incompatible live donor liver transplantation in children,thereby offering valuable insights for clinical practice in this particular area.Methods The data of 22 children who underwent living donor liver transplantation in the Department of Pediatric Surgery,the First Affiliated Hospital of Xinjiang Medical University from 2021 to 2023 were retrospectively analyzed.There were 16 cases in the ABO-identical(ABO Id)or ABO-compatible(ABO-C)group.There were 6 cases in the ABO-incompatible(ABO-In)group.The general data,postoperative indicators,complications and survival of the two groups were compared.Results There was no statistically significant difference between the two groups in transplant age,gender,operation history,PELD score,donor age,anhepatic phase,operation time,postoperative hospitalization duration,tacrolimus whole blood trough concentration,and serum creatinine value(P＞0.05).There was no significant difference in the overall cumulative survival rate between the two groups(P＞0.05).There was no significant difference in the incidence of postoperative pulmonary infection,cytomegalovirus infection,rejection and vascular complications between the two groups(P＞0.05).Conclusion ABO incompatible living donor liver transplantation in children is a safe and effective treatment,which can increase the source of donor liver and save the lives of children.
基金项目
2023天山英才人才培养计划(TSYC202301A072)
新疆维吾尔自治区重点研发任务专项项目资助(2023B03018-2)
维普
万方数据